Wed, Oct 22, 2014, 10:24 AM EDT - U.S. Markets close in 5 hrs 36 mins


% | $
Quotes you view appear here for quick access.

Microsoft Corporation Message Board

infocanhelp 1172 posts  |  Last Activity: 2 hours 16 minutes ago Member since: Jul 25, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • infocanhelp infocanhelp 2 hours 16 minutes ago Flag

    it seems many FUDs here disregard credibility and simply post from a script prepared by some hedge fund bot. Who knows, maybe the bot is now also programmed to post directly?

  • Reply to

    Obola golfing again - October 18, 2014

    by president_obola Oct 18, 2014 7:14 PM
    infocanhelp infocanhelp Oct 18, 2014 7:35 PM Flag

    did he get a obola-in-one?

  • The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection. Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection. It is also the first approved regimen that does not require administration with interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection. Both drugs in Harvoni interfere with the enzymes needed by HCV to multiply. Sofosbuvir is a previously approved HCV drug marketed under the brand name Sovaldi. Harvoni also contains a new drug called ledipasvir. “With the development and approval of new treatments for hepatitis C virus, we are changing the treatment paradigm for Americans living with the disease,” said Edward Cox, M.D., M.P.H., director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research. “Until last year, the only available treatments for hepatitis C virus required administration with interferon and ribavirin. Now, patients and health care professionals have multiple treatment options, including a combination pill to help simplify treatment regimens.” Harvoni is the third drug approved by the FDA in the past year to treat chronic HCV infection. The FDA approved Olysio (simeprevir) in November 2013 and Sovaldi in December 2013.

  • Reply to


    by phantomgarth Oct 12, 2014 3:36 PM
    infocanhelp infocanhelp Oct 12, 2014 3:42 PM Flag

    patient recently traveled to West Africa.

  • not a bad entry point, imho

  • infocanhelp by infocanhelp Sep 10, 2014 8:59 AM Flag

    It's sad that the pricing for an AAPL entry point is based so heavily on market manipulation as opposed to the facts that will determine the future company profitability. Guess this is why so many wealthy investors speak so highly about naysayers that provide lower entry points. Discounted shares could be a good entry point today? Maybe tomorrow? Will make no difference in 6 months when the valuation is based on the fact that will be demonstrated by good consumer acceptance of all the new technologies presented yesterday. I fully understand that many naysayers fail to comprehend the true value at this point.

  • Reply to


    by billyteex1 Sep 5, 2014 3:28 PM
    infocanhelp infocanhelp Sep 5, 2014 6:11 PM Flag

    My point exactly, billyteex1, since under the initial partnership Teva has the option to further invest for the development of two additional antiviral or antibacterial drugs that will result in Teva owning approximately 23% of Cocrystal. I'm not sure even sure whether 23% is still valid today given the lawsuit, recent Frost purchases, and other factors that have occurred since 2011. Are you referring to a possible separate partnership in your initial "MSLP" post? I'm sure TEVA is already apprised on the status of preclinical work at Cocrystal. Thanks for clarifying.

  • Reply to


    by billyteex1 Sep 5, 2014 3:28 PM
    infocanhelp infocanhelp Sep 5, 2014 3:54 PM Flag

    I believe COCP already has a partnership with TEVA that was consummated 15SEP11. Maybe the terms will be updated? Under the terms of the initial agreement, Teva will initially invest $7.5 million in CDI (now Cocrystal), and the Company will develop for Teva an antiviral drug targeting the polymerase enzyme of the Hepatitis C virus. Upon completion of the initial development plan, Teva will have the option to make additional investments under certain milestones. Teva will have the right to exclusively license the drug for further development and commercialization, under agreed-upon commercial terms. “We are delighted with this investment from Teva, a leading global company that develops important new medicines bringing value to patients,” said Nobel Laureate Roger Kornberg, Ph.D., Chief Scientist at CDI and member of the Board of Directors of Teva. “Through this agreement, CDI is now ideally placed to accelerate the development of our novel platform, which combines high resolution X-ray crystallography with unique and advanced computational methods. It is our hope we can yield new and better drugs for the treatment and prevention of many viral diseases."

  • Reply to

    Did anyone see Sunday's New York Times?

    by bobstewart1952 Aug 26, 2014 1:31 AM
    infocanhelp infocanhelp Aug 26, 2014 8:05 AM Flag

    News about Castle Brands Inc., including commentary and archival articles published in The New York Times.

    Company Information

    Castle Brands Inc. develops and markets beverage alcohol categories. Its beverage alcohol categories includes rum, whiskey, liqueurs, vodka and tequila. It distributes its products in all 50 states in the United States and the District of Columbia, in thirteen primary international markets, including Ireland, Great Britain, Northern Ireland, Germany, Canada, South Africa, Bulgaria, France, Russia, Finland, Norway, Sweden, China and the Duty Free markets, and in a number of other countries in continental Europe and Latin America. It markets brands, including Gosling's Rum, Gosling's Stormy Ginger Beer, Gosling's Dark ‘n Stormy ready-to-drink cocktail, Jefferson's, Jefferson's Reserve and Jefferson's Presidential Select bourbons, Jefferson's Rye whiskey, Pallini liqueurs, Clontarf Irish whiskey, Knappogue Castle Whiskey, Brady's Irish Cream, Boru vodka, Tierras TM tequila, Celtic Honey liqueur, Castello Mio sambucas, Travis Hasse's Original Pie liqueurs and Gozio amaretto.

  • Reply to

    Does OPK own shares in COCP

    by jackegan99 Aug 17, 2014 7:41 AM
    infocanhelp infocanhelp Aug 17, 2014 12:44 PM Flag

    You hedgies, adjack, are comical always trying to cover your tracks. Hilarious how adsmith2036 quickly replies to jackegan99 1 hour and 31 minutes after my observation the two poster names coincide visually on the YMB. All you hedgies do is pump it up and later bash it down, or vice versa. Funny how info can help clarify posts.

  • Reply to

    Does OPK own shares in COCP

    by jackegan99 Aug 17, 2014 7:41 AM
    infocanhelp infocanhelp Aug 17, 2014 7:57 AM Flag

    Interesting that your post is listed on the YMB as being done by adsmith2036. Funny how info can help clarify some posts.

  • infocanhelp by infocanhelp Aug 14, 2014 12:50 PM Flag

    why do people post "saving" negative stock information on a public message board? What do they have to gain by doing so? Is it their resurrection? A way to trick investors? Total rubbish is what I say.

  • Reply to

    Big buy by Kim

    by hairy261 Aug 12, 2014 4:39 PM
    infocanhelp infocanhelp Aug 12, 2014 5:46 PM Flag

    Is he on the list of INO longs?

  • Reply to


    by drangles2000 Aug 8, 2014 5:56 PM
    infocanhelp infocanhelp Aug 10, 2014 12:06 PM Flag

    up a little over 3.5%

  • can the INO TEAM respond to this adventure like they did earlier to the AF swipe? Some investors might be interested to know what fish they're trying to hook.

  • Reply to

    Did Russia just attack Walgreens?

    by damnitjim60 Aug 5, 2014 2:28 PM
    infocanhelp infocanhelp Aug 5, 2014 2:47 PM Flag

    5 percent drop on increased sales ... tells me there is some insider news that will eventually be under scrutiny by Congress and others.

  • was is banned or did they just give up on the concept? what happens to people that were using the service?

  • Reply to

    The Street

    by billyrc2002 Jul 24, 2014 10:21 AM
    infocanhelp infocanhelp Jul 24, 2014 10:30 AM Flag

    Scott Olson, the Street author, graduated from the University of Massachusetts in 1999 with a bachelors in English prior to moving to California and working with the founders of Trade Ideas at FutureTrade Tech. I heard he shares a cube with AF @ The Street.

  • Reply to

    I think I figured out who uncle is!!!

    by chuck_2_2000 Jul 10, 2014 9:03 AM
    infocanhelp infocanhelp Jul 21, 2014 8:54 AM Flag

    Is the uncle on holiday?

  • infocanhelp infocanhelp Jul 16, 2014 3:25 PM Flag

    Try using ignore brand bug spray to eliminate the nuisance.

44.805-0.075(-0.17%)10:24 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.